After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom

After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom

Source: 
Endpoints
snippet: 

For the past 6 months, Cytokinetics $CYTK CEO Robert Blum has been holding things together in the wake of a devastating late-stage disaster that swept away its lead muscle drug.